Compare Moderna, Inc. (MRNA) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Phillips 66 — how do they compare? Moderna, Inc. trades at $63.93 (market cap $25.42B), while Phillips 66 trades at $226.69 (market cap $90.01B). The key difference: Phillips 66 is far larger — about 3.5× Moderna, Inc.'s market cap, and Phillips 66 pays a 2.25% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | PSX | |
|---|---|---|
Market Cap | $25.42B | $90.01B |
Sector | Health | Energy |
52-Week High | $81.80 | $225.58 |
52-Week Low | $22.36 | $122.17 |
Enterprise Value | $21.57B | $106.48B |
Dividend Yield | — | 2.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Phillips 66 (PSX) trades at $225.48, up 4.62% today, with a bullish technical signal supported by moving averages and strong earnings beats. Recent Q2 2026 EPS of $9.41 exceeded expectations, driven by robust refining margins. The company announced a $5 billion joint venture for the Western Gateway Pipeline, signaling growth in midstream operations. Valuation metrics appear attractive with a P/E of 12.81 and P/S of 0.6, while profitability remains solid with a 24.02% ROE.
Outlook is positive due to sustained refining tightness and debt reduction, but risks include volatile crude prices and regulatory pressures. Analysts are bullish with a $221.92 consensus target, though the stock faces near-term resistance at $227. Revenue is projected to rebound to $152.2B in 2026, supporting a hold or buy stance for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
